BYSI - Kewajiban jangka dawa marang modal BeyondSpring Inc.

BeyondSpring Inc. (BYSI) is currently restructuring its programs and shifting its strategy toward the Asian market due to regulatory challenges in the US. This debt-to-equity chart illustrates leverage dynamics, with the indicator currently at 0.00. Conflicts between Washington and Beijing are hindering the recognition of tests and the export of pharmaceuticals. Risks are further compounded by overseas patent complications and raw material supply chain issues.

This indicator compares liabilities with a maturity of over one year against equity to assess long-term solvency. The long-term debt-to-equity ratio demonstrates the extent of the business's reliance on external borrowing. For BeyondSpring Inc. (BYSI), this balance is critical due to liquidity shortages and FDA regulatory risks. The long-term debt-to-equity trend reveals the margin of safety in the event of potential clinical trial delays. Minimal debt leverage here serves as the sole barrier against bankruptcy.